Instructions

Here are the suggested instructions for use of the NEPTUNE calculator in English, specifying that the required data is readily accessible:

Instructions for use of the NEPTUNE calculator:

1. Gather the clinical and pathological details of the patient with neuroendocrine tumor (NET) under consideration for 177Lu-DOTATATE therapy. You can obtain the necessary information from the patient's medical records or directly from the patient, avoiding the need for complex additional tests. This means that you can determine the variables before referring the patient to the nuclear medicine department.

Required Information:

• ECOG performance status
• Primary tumor subtype (origin)
• Krenning score
• Type of metastasis
• Ki67 proliferation index
• Time from cancer diagnosis to the start of PRRT
• Number of prior lines of systemic therapy

2. Enter the gathered information into the calculator. It will automatically generate a personalized estimate of the expected progression-free survival (PFS) for the patient following 177Lu-DOTATATE treatment.

3. Review the estimated PFS displayed on the survival curve. Utilize the generated prognostic score to assist in making informed decisions regarding the appropriateness of 177Lu-DOTATATE therapy for the specific case.

4. The NEPTUNE calculator is intended as an initial screening tool in the selection process for patients for peptide receptor radionuclide therapy (PRRT). Should further evaluation in nuclear medicine be required, this early prediction can later be refined with additional comprehensive molecular data.

5. For any inquiries or feedback, please do not hesitate to contact us via enlace al contacto